Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial.

Gargiulo, Giuseppe; Esposito, Giovanni; Cirillo, Plinio; Nagler, Michael; Minuz, Pietro; Campo, Gianluca; Gragnano, Felice; Manavifar, Negar; Piccolo, Raffaele; Avvedimento, Marisa; Tebaldi, Matteo; Wahl, Andreas; Hunziker, Lukas; Billinger, Michael; Heg, Dik; Windecker, Stephan; Valgimigli, Marco (2020). Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial. (In Press). Journal of cardiovascular translational research JCTR Springer 10.1007/s12265-020-09969-4

[img] Text
Gargiulo JCardiovascTranslRes 2020_epub.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (853kB) | Request a copy
[img] Text
Gargiulo JCardiovascTranslRes 2020_AAM.pdf - Accepted Version
Restricted to registered users only until 25 February 2021.
Available under License Publisher holds Copyright.

Download (475kB) | Request a copy

Antithrombotic therapy is a critical component of the management of ST-elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI). Rapid and profound inhibition of platelet reactivity has been shown to mitigate the ischemic risks and improve myocardial salvage. High residual platelet reactivity (HRPR) has been reported up to 4 or 6 h after loading dose of prasugrel or ticagrelor; therefore, multiple alternative strategies, including crushed or chewed oral tables or intravenous agents, have been investigated to provide a more rapid and sustained inhibition of platelet function and bridge the initial treatment gap. The FABOLUS FASTER is the first investigator-initiated, multicentre, open-label, prospective, randomized study to directly compare the pharmacodynamics effects of cangrelor, tirofiban, chewed or integer prasugrel. This study will add new insights in the management of antiplatelet therapy in patients with STEMI undergoing primary PCI and might be hypothesis-generating for future clinical trials in this field. The trial is registered on clinicaltrials.gov NCT02978040, and EudraCT 2017-001065-24.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry

UniBE Contributor:

Gargiulo, Giuseppe; Nagler, Michael; Manavifar, Negar; Wahl, Andreas; Hunziker Munsch, Lukas Christoph; Billinger, Michael; Heg, Dierik Hans; Windecker, Stephan and Valgimigli, Marco

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1937-5387

Publisher:

Springer

Language:

English

Submitter:

Andrea Flükiger-Flückiger

Date Deposited:

13 Mar 2020 18:11

Last Modified:

01 Apr 2020 08:53

Publisher DOI:

10.1007/s12265-020-09969-4

PubMed ID:

32096064

Uncontrolled Keywords:

Cangrelor Platelet aggregation Prasugrel Primary PCI Tirofiban

BORIS DOI:

10.7892/boris.141278

URI:

https://boris.unibe.ch/id/eprint/141278

Actions (login required)

Edit item Edit item
Provide Feedback